About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome

NCT07173062·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Francisca Saraiva, PhD
CONTACT
220426820 f.saraiva@med.up.pt
Janete Santos, PhD
CONTACT
961239890 investigaclinica@med.up.pt

Lead

Universidade do Porto

With

Centro Hospitalar De São João, E.P.E.

Age

50–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

≥50 years
BMI ≥20 kg/m2
History of stroke, coronary artery disease, myocardial infarction, peripheral artery disease, chronic kidney disease (eGFR \<75 ml/min at least for 3 months), albuminuria \>300 mg/g, or diabetes mellitus
No antibiotics in the previous 30 days
If a woman, she must be a woman of non-childbearing potential. That is, she must be:
* Surgically sterilized (e.g. underwent hysterectomy, bilateral salpingectomy or bilateral oophorectomy);
* Clinically diagnosed infertile;
* In a post-menopausal state, defined as no menses for 12 months without an alternative medical cause.
A woman patient of childbearing potential must have a negative serum pregnancy test at Visit 0 (Day 0) and must agree to use consistently and correctly (from 28 days prior to first study treatment administration until at least 7 days after last study treatment administration) one of the following highly effective methods of contraception:
* Abstinence of heterosexual intercourse (when this is in line with preferred and usual lifestyle of the subject);
* Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);
* Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal);
* Intrauterine device;
* Intrauterine hormone-releasing system;
* Bilateral tubal occlusion;
* Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner.

You may not be if

Unwilling to sign the informed consent form (if the patient wants to participate but cannot sign for any reason, then a third-person testimony may sign/complete the informed consent form on the patient's behalf).
Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).
Participation in another clinical study with an investigational product during the last month.

The record

StatusRecruiting

PhaseNot applicable

Taking part150

StartedMar 2025

UpdatedSep 15, 2025

Conditions

Stroke Coronary Arterial Disease (CAD)Myocardial Infarction (MI)Diabetes Mellitus Peripheral Artery Disease (PAD)+2

Where1

Unidade Local de Saúde de São João
Porto, Portugal